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The class III phosphoinositide 3-kinase VPS34 regulates autophagosome formation. Three groups have developed VPS34 inhibitors and shown their utility in investigating and defining autophagic processes.
Macroautophagy (commonly called autophagy) is a lysosomal pathway that degrades and recycles diverse cytosolic components in response to nutrient deprivation and a wide array of other stresses. The pressing need for identification of autophagy-specific pharmacological inhibitors remains, as autophagy is a critical metabolic adaptation and homeostatic process in many cellular contexts and diseases, including neurodegeneration and cancer 1 . One protein that has attracted immense interest as a potential target to inhibit autophagy is the class III phosphoinositide 3-kinase (PI3K) vacuolar protein sorting 34 (VPS34), the most ancient and conserved PI3K isoform in eukaryotes that generates intracellular pools of phosphatidylinositol 3-phosphate (PtdIns(3)P) 2, 3 . VPS34 forms two distinct complexes that localize either at preautophagosomal structures (VPS34-VPS15-ATG14-UVRAG-Beclin1) or at endosomes (VPS34-VPS15-UVRAG-Rab5-EEA1) (Fig. 1) 
4
. VPS34 activity generates intracellular PtdIns(3)P, which is incorporated into the membranes of vesicular organelles, including autophagosomes and endosomes. This leads to the recruitment of adaptor proteins possessing PtdIns(3)P-binding FYVE and PX domains, thereby enabling diverse organelle functions including membrane trafficking and signal transduction with high spatiotemporal specificity 5 . Reporting in Nature Cell Biology, Dowdle et al. have identified the small molecule PIK-III as a pharmacological inhibitor of VPS34 and demonstrate its efficacy as an autophagy inhibitor 6 . Two additional groups report the development of distinct inhibitors of VPS34 (SAR405 and VPS34-IN1, respectively) that cause defects in autophagosome formation and endosomal trafficking 7, 8 . All three VPS34 inhibitors are exquisitely selective for the class III PI3K VPS34 and not the closely related class I and class II PI3Ks.
Initial work using these three distinct inhibitors clearly demonstrates VPS34 control of autophagy and suggests important roles for VPS34 at endosomes. Dowdle et al. demonstrate that PIK-III treatment decreases autophagosome formation, leading to an accumulation of known substrates (NBR1, p62/ SQSTM1, NDP52) that are normally degraded by the autophagy pathway 9 . The Pasquier group similarly shows that starvation-induced autophagy is completely abrogated by the VPS34 inhibitor SAR405 (ref. 7) . Finally, the Alessi group delineates distinct effects for their VPS34 inhibitor VPS34-IN1 on endosome biogenesis 8 . These studies reveal an 80% loss in endosomal labelling following VPS34-IN1 treatment, measured using a GFP-FYVE fusion protein as a reporter of intracellular PtdIns(3)P production. Notably, cells still exhibit residual GFP-FYVE vesicular labelling, suggesting that VPS34-independent pathways may contribute to PtdIns(3)P generation and endosome formation. Additionally, the Alessi group demonstrates that VPS34 inhibition impacts the localization of serum-and glucocorticoid-regulated kinase-3 (SGK3), the only protein kinase known to interact specifically with PtdIns(3)P via its N-terminal PX domain, to EEA1-positive endosomes, resulting in defective SGK3 phosphorylation. Although the functional significance of VPS34 inhibition on endocytosis and SGK3 activity requires further investigation, these studies illustrate that pharmacological VPS34 inhibition has the potential to impact multiple PtdIns(3)P-dependent intracellular processes and reinforce that these agents should not be construed as being autophagy-specific.
Nevertheless, the importance of these VPS34 inhibitors as tools in autophagy research is poignantly illustrated through their utility in identifying putative autophagy substrates, both autophagy cargo receptors and autophagic targets. While initially viewed to be a non-selective bulk degradation pathway, autophagy is now appreciated as a selective process that targets specific proteins and organelles, via autophagy cargo receptors, for lysosomal degradation, termed 'selective autophagy' 9 . Several autophagic receptors, such as p62/SQSTM1, NBR1, OPTN and NDP52 have been identified using genetic ablation of autophagy-related genes (ATGs) or chemical lysosomal inhibitors disrupting autophagic degradation. Nevertheless, the identification of autophagic substrates has been a challenge due to the lack of specificity of pharmacological inhibitors and low overlap between datasets 10 . Accordingly, Dowdle et al.
used quantitative liquid chromatography-mass spectrometry analysis (LC-MS) of cells treated with PIK-III to identify several autophagy substrates and candidate autophagic receptors. Because proteins targeted for autophagic degradation are commonly ubiquitinated 9 , the authors took advantage of a proteomics strategy interrogating both diglycyl-enriched ubiquitinated peptides as well as the global proteome of cells treated with PIK-III. Using this approach, NCOA4 emerged as a top hit, second only to the known autophagy receptor NBR1. Interestingly, TMEM59, a protein shown to target endosomal membranes for autophagic degradation 11 , was another top hit in the LC-MS analysis, suggesting potential interactions between endosomal and autophagic pathways.
Notably, a recent proteomics study by Mancias et al. similarly uncovered NCOA4 as an autophagosome-enriched protein 10 ; hence, these experiments independently verify NCOA4 as a bona fide autophagy substrate. The authors demonstrate that NCOA4 protein accumulates in cells treated with PIK-III or the lysosomal inhibitor bafilomycin A, while NCOA4 mRNA remains unchanged. Furthermore, starved cells undergoing autophagy degrade NCOA4 in a time-dependent manner similar to known autophagy receptors. Although NCOA4 was originally hypothesized to be a co-activator of the nuclear androgen receptor (AR) 12 , the discovery of its autolysosomal localization suggests otherwise. Hence, the authors utilized streptavidin-purified NCOA4 to reveal candidate cargos via unbiased LC-MS and identified ferritin heavy chain (FTH1) and ferritin light chain (FTL), the two principal components of a large multi-subunit complex capable of storing and chelating intracellular iron. In conditions of low iron bioavailability, these ferritin complexes are lysosomally degraded, giving rise to increased bioavailable iron. Although genetic studies suggested a requirement for autophagy in ferritin degradation 13, 14 , the precise mechanisms by which ferritin is targeted for autophagic degradation have been unclear until the recent study by Mancias et al. uncovering NCOA4 as a potential autophagy cargo receptor mediating ferritin turnover 10 . Dowdle et al. now corroborate and expand these findings. They demonstrate that FTH1 and FTL levels are decreased upon nutrient starvation in an FTH1-dependent manner. Notably, NCOA4, FTH1 and FTL all co-localize with LAMP2-positive autolysosomes but not with EEA1-positive endosomes. Upon deleting NCOA4 in DLD1 cells using clustered regularly interspaced short palindromic repeats (CRISPR) technology, FTH1 and FTL accumulate even under starvation conditions. Finally, treatment of NCOA4
-/-cells with deferasirox (DFX), which promotes the autophagic degradation of ferritin complexes, does not promote the turnover of FTH1 and FTL. These results indicate that intracellular iron bioavailability is regulated by NCOA4-dependent autophagic degradation of ferritin complexes (Fig. 2) .
Due to the requirement of iron in many biological reduction and oxidation reactions and the high toxicity of excess iron, pharmacological regulation of intracellular iron stores has important implications for diseases such as anaemia (iron deficiency) and haemochromatosis (excess iron). Bioavailable iron regulates haeme biogenesis, erythroid cell development and erythropoiesis. Furthermore, excess iron accumulation in a wide range of tissues can lead to oxidative damage, mediated by Fentonlike reactions that generate hydroxyl radicals and reactive oxygen species 15 . Dowdle et al. probe NCOA4 function in vivo by generating chimeric mice with CRISPR-deleted NCOA4 embryonic stem cells. These animals exhibit profound accumulation of intracellular iron deposits in macrophages of the splenic red pulp compared to wild-type chimeric animals. Hence, one can speculate that VPS34 inhibition of NCOA4-mediated selective autophagic degradation of ferritin complexes will have an untold side effect in vivo -accumulation of iron deposits and reduced iron bioavailability. Future in vivo studies are required to determine the potential of these novel VPS34 inhibitors as pharmaceutical agents and will undoubtedly uncover novel effects of autophagy inhibition in the context of human disease. Additionally, the use of VPS34 inhibitors in conjunction with specific class I PI3K inhibitors endows researchers with a strategy to study the poorly understood class II PI3Ks.
Overall, the promise of specific, pharmacological inhibition of VPS34 has opened up exciting scientific possibilities that will undoubtedly expand our understanding of both autophagic and endocytic processes.
